Halozyme (NASDAQ:HALO) sales jumped 200% this quarter, coming in at $16 million compared to Q3 2012's $5.3 million, according to results the company released today. The biopharmaceutical company's success was largely attributed to $7.9 million in sales of products including Halozyme's proprietary treatment ingredient, recombinant human hyaluronidase (rHuPH20), as well as $3.7 million paid from collaborators for research services reimbursements.
The quarter also saw growth in its profit margins, but not nearly on the same scale as its revenue. Halozyme's operating loss narrowed 7%, to $18.4 million, while its net loss shrunk 3% to $19.3 million. On the balance sheet, Halozyme's cash, cash equivalents, and marketable securities were $65.3 million at Sept. 30, 2013, compared with $76.0 million at June 30, 2013 and $99.5 million at December 31, 2012
In a statement, Halozyme CEO and President Gregory Frost said the last quarter was "remarkable" for Halozyme's European commercial launches of HyQvia and Herceptin SC, "each leveraging Halozyme's proprietary rHuPH20 technology to deliver more efficient treatment options." Frost also noted that data are emerging within the company's development programs "supporting the hypothesis that patients with high hyaluronan tumor levels may benefit most from PEGPH20 therapy in the treatment of pancreatic cancer."
Editor's note: This story has been updated to reflect Halozyme's cash, cash equivalents, and marketable securities figures, and the headline has been updated.